ARPA-H, part of HHS, has earmarked up to $142 million for 10 research projects building the tools, data, and infrastructure needed to tackle treatment resistance.

Based on data from the BEACON and NAUTICAL studies, regulatory authorities greenlit the combo for later-line patients.

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

NEW YORK – CAR T-cell therapy developer Cargo Therapeutics earlier this week announced it will be bought by Concentra Biosciences.

The drug, which Repare recently sidelined, has shown promising activity in a patient with ALT-positive melanoma that researchers want to study in others.

The funds will help the firm advance copper-based radioligand therapies and imaging agents in prostate, neuroendocrine, and breast cancers.

The biotech will add a pivotal Phase III cohort to its ongoing Phase I/II trial evaluating ATSN-201 in X-linked retinoschisis ...

The biotech firm eliminated the need for surgical administration in the study by using an infusion catheter system in a cardiac cath lab.

The Whitrod family launched Genetic Cures for Kids in the hopes of finding a treatment for their daughter with hereditary ...

The firm will use the money to advance its lead FAP-targeting radioligand candidate into clinical development.

The firm will use the funds to conduct a Phase I/II trial of an adoptive cell therapy designed to activate T regulatory cells against cancer.